Literature DB >> 6491988

Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice.

B F Bourgeois, N Wad.   

Abstract

Anticonvulsant effect and neurological toxicity were investigated in mice for carbamazepine (CBZ) and its main metabolites, carbamazepine-10,11-epoxide (CBZ-E) and 10,11-dihydro-10,11-trans-dihydroxy-CBZ. The compounds were first tested separately and the results were expressed in terms of brain concentrations. Brain penetration was very poor for 10,11-dihydro-10,11-trans-dihydroxy-CBZ, which had neither anticonvulsant nor neurotoxic activity. Against maximal electroshock, CBZ was slightly more potent than CBZ-E and both were ineffective against pentylenetetrazole and bicuculline. CBZ and CBZ-E displayed similar neurotoxicity. Combined administration of CBZ and CBZ-E revealed a slightly synergistic interaction with regard to both anticonvulsant and neurotoxic action, the therapeutic index of the mixture being similar to that of CBZ. These results suggest that antiepileptic activity and neurological toxicity of CBZ are proportional to the sum of the concentrations of CBZ and its metabolite CBZ-E. Furthermore, variable levels of CBZ-E in relation to CBZ do not affect the overall therapeutic index. Finally, the results do not indicate that CBZ-E alone has any advantage over CBZ with regard to neurotoxic side-effects and therapeutic index.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491988

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 2.  Treatment of epilepsy in pregnancy.

Authors:  I Nulman; D Laslo; G Koren
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

4.  Dose-dependent pharmacokinetics of carbamazepine in rats: determination of the formation clearance of carbamazepine-10,11-epoxide.

Authors:  R P Remmel; M W Sinz; J C Cloyd
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

5.  Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine.

Authors:  Nahla S Barakat; Ibrahim M Elbagory; Alanood S Almurshedi
Journal:  AAPS PharmSciTech       Date:  2008-08-07       Impact factor: 3.246

6.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat.

Authors:  S R Weiss; T Nguyen; D R Rubinow; C J Helke; P K Narang; R M Post; D M Jacobowitz
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.

Authors:  J J Muñoz; R E De Salamanca; C Diaz-Obregón; F L Timoneda
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

8.  The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients.

Authors:  Chahra Chbili; Anis Hassine; Aicha Laouani; Sana Ben Amor; Manel Nouira; Sofiène Ben Ammou; Saad Saguem
Journal:  Arch Med Sci       Date:  2016-05-20       Impact factor: 3.318

9.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335

10.  Markedly Elevated Carbamazepine-10,11-epoxide/Carbamazepine Ratio in a Fatal Carbamazepine Ingestion.

Authors:  Jason L Russell; Henry A Spiller; Daniel D Baker
Journal:  Case Rep Med       Date:  2015-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.